The master's thesis addresses the challenges associated with Pseudomonas aeruginosa, one of the most important opportunistic pathogens in modern medicine. Its ability to form biofilms and its high level of resistance to antibiotics significantly contribute to persistent and difficult treatment of infections. A biofilm is a complex three-demensional structure of microoganisms embedded in an extracellular polimeric matrix, which protects bacteria from enviromental stress, host immune responses, and antimicrobal agents. Consequently, biofilm-associated infections are often chronic, require prolonged treatment, and represent a substantial burden on healthcare systems. The main objective of this research was to evaluate the biofilm-forming capacity of different strains of P. aeruginosa and to determine the inhibitory effect of selected compounds from compound library on biofilm formation. A total of 1136 compounds were screened using a standardized microtiter plate assay. Biofilm formation was quantified using crystal violet staining and absorbance measurments at 584 nm. The results demonstrated significant variability in biofilm formation among different P. aeruginosa strains, highlighting the importance of genetic background and isolate origin. Some clinical and enviromental strains from milk exhibited a higher biofilm-forming capacity than the reference strain PAO1, emphasizing the complexity of the problem. Screening identified several compounds capable of inhibiting biofilm formation by 50 % or more. Subsequent validation confirmed the antibiofilm potential of several candidates, indicating their promise for further development. The discussion highlights that targeting biofilm formation represents a promising strategy for improving infection treatment, as it reduces bacterial virulence rather than directly killing bacteria, potentially limiting the development of antibiotic resistance. However, the study also acknowledges limitations, particularly the use of in vitro models, that may not fully reflect in vivo conditions. In conclusion, understanding the mechanisms of biofilm formation and identifying effective inhibitors are crucial steps toward developing new therapeutic approaches for managing P. aeruginosa infections. Further research should focus on optimizing the identified compounds and evaluating their efficacy in more complex and clinically relevant models.
|